Arcus Biosciences, Inc. (RCUS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on June 1, 2025, by Arcus Biosciences, Inc., a Delaware corporation. The filing discloses updated information regarding the Company's portfolio and development programs, specifically focusing on interim data from the Phase 1/1b clinical trial ARC-20.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements.
Material Changes and Clinical Data
The Company presented interim analysis data from the ARC-20 study evaluating the combination of casdatifan (100mg once-daily) and cabozantinib (60mg once-daily) in patients with clear cell renal cell carcinoma who progressed on prior immunotherapy. The data cutoff date was March 14, 2025.
- Efficacy Population: 24 patients (minimum 12 weeks follow-up or discontinued due to progression/adverse event).
- Safety Population: 42 patients (at least one month of safety follow-up).
- Median Follow-Up: 5.3 months.
- Confirmed Objective Response Rate (cORR): 46% (95% CI: 26, 67).
- Best Overall Response Breakdown:
- Complete Response: 4% (1 patient).
- Partial Response: 42% (10 patients; inclusive of one confirmed after the data cutoff).
- Stable Disease: 50% (12 patients).
- Progressive Disease: 4% (1 patient).
- Safety Profile: No unexpected safety risks were identified. The combination demonstrated an acceptable safety profile with no meaningful overlapping toxicity between the two drugs.
Guidance, Outlook, and Risks
Management commentary is limited to the disclosure of the updated corporate presentation and the specific clinical data points listed above. The filing does not provide forward-looking financial guidance, updated commercial outlook, or specific risk factors beyond the standard clinical trial context. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the full text of the updated corporate presentation posted on the Company's Investors & Media website.
- Confirm the final analysis results of the ARC-20 Phase 1/1b study once the trial concludes.
- Review the Company's most recent 10-K or 10-Q filings for current financial position, cash runway, and liquidity status, as this 8-K contains no financial data.
- Monitor regulatory communications regarding the potential advancement of the casdatifan and cabozantinib combination into later-stage trials.